An evaluation by Bunnell et.al. highlighted the potential adverse consequences of cost-related non-adherence to oral vancomycin therapy and the challenges that clinicians face when prescribe oral vancomycin capsules.
Product packaging and imagery are for representation purposes only and shall constitute the property of Azurity and all applicable affiliates.
The Information contained herein, including product information, is intended only for residents of the United States.
© 2019-2024 Azurity Pharmaceuticals, Inc. All Rights Reserved. All Trademarks referred to are the property of their respective owners.
PP-FKS-US-0095
